These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 29889862)

  • 41. Longitudinal Viral Suppression Among a Cohort of Adolescents and Young Adults with Behaviorally Acquired Human Immunodeficiency Virus.
    Wood SM; Lowenthal E; Lee S; Ratcliffe SJ; Dowshen N
    AIDS Patient Care STDS; 2017 Sep; 31(9):377-383. PubMed ID: 28891717
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Viral load monitoring for people living with HIV in the era of test and treat: progress made and challenges ahead - a systematic review.
    Pham MD; Nguyen HV; Anderson D; Crowe S; Luchters S
    BMC Public Health; 2022 Jun; 22(1):1203. PubMed ID: 35710413
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Frequency of Viremic Episodes in HIV-Infected Women Initiating Antiretroviral Therapy During Pregnancy: A Cohort Study.
    Myer L; Dunning L; Lesosky M; Hsiao NY; Phillips T; Petro G; Zerbe A; McIntyre JA; Abrams EJ
    Clin Infect Dis; 2017 Feb; 64(4):422-427. PubMed ID: 27927852
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.
    Haas AD; Keiser O; Balestre E; Brown S; Bissagnene E; Chimbetete C; Dabis F; Davies MA; Hoffmann CJ; Oyaro P; Parkes-Ratanshi R; Reynolds SJ; Sikazwe I; Wools-Kaloustian K; Zannou DM; Wandeler G; Egger M;
    Lancet HIV; 2015 Jul; 2(7):e271-8. PubMed ID: 26423252
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Risk factors associated with unsuppressed viral load in HIV-1 infected patients at the first antiretroviral therapy in Morocco.
    Hicham T; Ilyas E; Tarik H; Noureddine B; Omar B; Rachid F; Naoufal H; Mohammed B
    Int J Mycobacteriol; 2019; 8(2):113-117. PubMed ID: 31210151
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Patterns of adherence to antiretroviral therapy and HIV drug resistance over time in the Stratall ANRS 12110/ESTHER trial in Cameroon.
    Meresse M; March L; Kouanfack C; Bonono RC; Boyer S; Laborde-Balen G; Aghokeng A; Suzan-Monti M; Delaporte E; Spire B; Carrieri MP; Laurent C;
    HIV Med; 2014 Sep; 15(8):478-87. PubMed ID: 24589279
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Trends in Prevalence of HIV-1 Drug Resistance in a Public Clinic in Maputo, Mozambique.
    Bila DC; Boullosa LT; Vubil AS; Mabunda NJ; Abreu CM; Ismael N; Jani IV; Tanuri A
    PLoS One; 2015; 10(7):e0130580. PubMed ID: 26151752
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Implementation and Operational Research: Correlates of Adherence and Treatment Failure Among Kenyan Patients on Long-term Highly Active Antiretroviral Therapy.
    Ochieng W; Kitawi RC; Nzomo TJ; Mwatelah RS; Kimulwo MJ; Ochieng DJ; Kinyua J; Lagat N; Onyango KO; Lwembe RM; Mwamburi M; Ogutu BR; Oloo FA; Aman R
    J Acquir Immune Defic Syndr; 2015 Jun; 69(2):e49-56. PubMed ID: 26009836
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Outcomes of protease inhibitor-based antiretroviral therapy amongst children and associated-factors in Yaoundé, Cameroon.
    Njom Nlend AE; Guessong CO; Nga Motaze AC; Soffo C; Koki Ndombo PO; Tsambang L; Fokam J
    PLoS One; 2019; 14(3):e0213900. PubMed ID: 30883591
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Implementation and operational feasibility of SAMBA I HIV-1 semi-quantitative viral load testing at the point-of-care in rural settings in Malawi and Uganda.
    Gueguen M; Nicholas S; Poulet E; Schramm B; Szumilin E; Wolters L; Wapling J; Ajule E; Rakesh A; Mwenda R; Kiyaga C; Balkan S
    Trop Med Int Health; 2021 Feb; 26(2):184-194. PubMed ID: 33159822
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Brief Report: Time to Repeat Viral Load Testing Among Unsuppressed Adolescents and Young Adults Living With HIV in Kenya.
    Mugo C; Wilson KS; Onyango A; Njuguna IN; Mburu CW; Richardson BA; Oyiengo L; Inwani I; John-Stewart G; Wamalwa DC; Kohler PK
    J Acquir Immune Defic Syndr; 2020 Dec; 85(5):606-611. PubMed ID: 32897936
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Timeliness of Point-of-Care Viral Load Results Improves Human Immunodeficiency Virus Monitoring in Nigeria.
    Chaplin B; Agbaji O; Reyes Nieva H; Olatunde B; Chang C; Mitruka K; Sule H; Dajel T; Zee A; Ahmed ML; Ahmed I; Okonkwo P; Rawizza H; Kanki P
    Clin Infect Dis; 2023 Feb; 76(3):e671-e680. PubMed ID: 35872644
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Early HIV viral load determination after initiating first-line antiretroviral therapy for indentifying patients with high risk of developing virological failure: data from a cohort study in a resource-limited setting.
    Alvarez-Uria G; Naik PK; Pakam R; Midde M
    Trop Med Int Health; 2012 Sep; 17(9):1152-5. PubMed ID: 22487689
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Misdiagnosis of HIV treatment failure based on clinical and immunological criteria in Eastern and Central Kenya.
    Joram SL; Paul G; Moses K; Stanley B; Isaac M; Allan G; Tom M; Lilian K; Mildred M
    BMC Infect Dis; 2017 Jun; 17(1):383. PubMed ID: 28577527
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HIV Viral Load Monitoring Frequency and Risk of Treatment Failure among Immunologically Stable HIV-Infected Patients Prescribed Combination Antiretroviral Therapy.
    Young B; Hart RL; Buchacz K; Scott M; Palella F; Brooks JT;
    J Int Assoc Provid AIDS Care; 2015; 14(6):536-43. PubMed ID: 26293905
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Near Point-of-Care HIV Viral Load: Targeted Testing at Large Facilities.
    Ganesh P; Heller T; Chione B; Gumulira J; Gugsa S; Khan S; McGovern S; Nhlema A; Nkhoma L; Sacks JA; Trapence C; Tweya H; Ehrenkranz P; Phiri S
    J Acquir Immune Defic Syndr; 2021 Feb; 86(2):258-263. PubMed ID: 33136821
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa.
    Boender TS; Hamers RL; Ondoa P; Wellington M; Chimbetete C; Siwale M; Labib Maksimos EE; Balinda SN; Kityo CM; Adeyemo TA; Akanmu AS; Mandaliya K; Botes ME; Stevens W; Rinke de Wit TF; Sigaloff KC
    J Infect Dis; 2016 Sep; 214(6):873-83. PubMed ID: 27402780
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High efficacy of first-line ART in a West African cohort, assessed by dried blood spot virological and pharmacological measurements.
    de Truchis P; Lê MP; Daou M; Madougou B; Nouhou Y; Moussa Saley S; Sani A; Adehossi E; Rouveix E; Saidou M; Peytavin G; Delaugerre C
    J Antimicrob Chemother; 2016 Nov; 71(11):3222-3227. PubMed ID: 27439522
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment as prevention in resource-limited settings: is it feasible to maintain HIV viral load suppression over time?
    Socías ME; Rotryng F; Lapadula P; Medrano M; Paz D; Stern L; Lambierto A; Pryluka D
    J Infect Dev Ctries; 2013 Aug; 7(8):593-9. PubMed ID: 23949294
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Leveraging routine viral load testing to integrate diabetes screening among patients on antiretroviral therapy in Malawi.
    Singano V; van Oosterhout JJ; Gondwe A; Nkhoma P; Cataldo F; Singogo E; Theu J; Ching'ani W; Hosseinpour MC; Amberbir A
    Int Health; 2021 Feb; 13(2):135-142. PubMed ID: 32556207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.